Abstract
The role of bone marrow transplantation is to restore lymphohematopoietic function of a recipient whose marrow has been destroyed, either by disease or by the preparative therapy employed in an attempt to eradicate the patient's lymphohematopoietic malignancy. The restoration of lymphohematopoietic function through the donor graft occurs in stages, requires several months, and is often not completed until 1 to 2 years after transplantation. These sequential steps of immuno-reconstitution are associated with a number of definable and predictable immune deficiencies and seem to be responsible for the pattern of complications that emerges after transplantation. Most of these complications are either the result of, or associated with, infections that also occur in an almost predictable pattern. In the various phases of immune deficiency following sequentially after transplantation, the humoral immune system is greatly affected, thus raising the possibility that passively administered antibodies in the form of immune globulin therapy might be beneficial in all phases of the marrow transplant procedure. This paper attempts to summarize the use of immune globulin preparations in clinical bone marrow transplantation, showing the rationale for and some of the results of therapeutic immune globulin administration.
Key words: Cytomegalovirus (CMV), graft-vs-host disease (GVHD), interstitial pneumonia, intravenous immune globulin (IVIG), total-body irradiation (TBI)
References
- 1.Tutschka PJ, Copelan EA, Klein J. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382–1388. [PubMed] [Google Scholar]
- 2.Storb R, Prentice RL, Buckner CD, et al. Graft versus host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: Beneficial effect of a protective environment. N Engl J Med. 1983;308:302–307. doi: 10.1056/NEJM198302103080602. [DOI] [PubMed] [Google Scholar]
- 3.Munsler AM. Infections in burns. In: Morell A, Nydegger UE, editors. Clinical Use of Intravenous Immunoglobulins. London: Academic Press; 1986. pp. 339–344. [Google Scholar]
- 4.Pollack M. Antibody therapy in gram-negative bacterial disease. In: Morell A, Nydegger UE, editors. Clinical Use of Intravenous Immunoglobulins. London: Academic Press; 1986. pp. 317–325. [Google Scholar]
- 5.Pollard M, Chang CF, Srivastava KK. The role of microflora in development of graft versus host disease. Transplant Proc. 1976;8:533–536. [PubMed] [Google Scholar]
- 6.Rossie KM, Sheridan JF, Barthold SW, Tutschka PJ. Graftvs-host disease and sialodacryoadenitis viral infection in bone marrow transplanted rats. Transplantation. 1988;45:1012–1016. doi: 10.1097/00007890-198806000-00003. [DOI] [PubMed] [Google Scholar]
- 7.Kapoor N, Copelan EA, Tutschka PJ. Cytomegalovirus (CMV) infection in bone marrow transplant recipients: Use of intravenous gammaglobulin as prophylactic and therapeutic agents. Transplant Proc. 1989;XXI:3095–3096. [PubMed] [Google Scholar]
- 8.Bratanow NC, Ash RC, Turner PA,et al.: Successful treatment of serious cytomegalovirus disease with 9(1,3-dihydroxy-2-propoxymethyl) guanine in bone marrow transplant (BMT) patients. Blood 68(5) Suppl 1:280a, 1986
- 9.Emanuel D, Peppard J, Chehimi J, Hammerling U, O'Reilly R. The diagnostic, prophylactic and therapeutic uses of monoclonal antibodies to human cytomegalovirus. Transplant Proc. 1987;XIX(6):132–137. [PubMed] [Google Scholar]
- 10.Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone marrow transplant recipients. N Engl J Med. 1982;306(17):1009–1012. doi: 10.1056/NEJM198204293061701. [DOI] [PubMed] [Google Scholar]
- 11.Copelan EA, Bechtel T, Featheringham NC, Grose MM, Sedmak DD, Kapoor N, Tutschka PJ. Oral administration of IgG in marrow transplant recipients. Drug Intell Clin Pharm. 1988;22:912. doi: 10.1177/106002808802201119. [DOI] [PubMed] [Google Scholar]
- 12.Al-Eid MD, Tutschka PJ, Wagner HN, Jr, Santos GW, Tsan MF. Functional asplenia in patients with chronic graft-versus-host disease: Concise communication. J Nucl Med. 1983;24:1123–1126. [PubMed] [Google Scholar]
- 13.Sheridan JF, Tutschka PJ, Sedmak D, Copelan EA. IgG subclass deficiency and pneumococcal pneumonia following allogeneic marrow transplantation. Blood. 1990;75(7):90–93. [PubMed] [Google Scholar]